97
CBD has been the evolutionary entry point conversation with medical Cannabis. For many it has removed many objections from Patients and Physicians who would otherwise never consume or consider Medical Cannabis due to euphoric effects and lack of research, efficacy and consistency. However, today the opportunity for the medical community to observe the therapeutic benefits comes with the baseline of all formulations being founded in the science. Thus creating an innovative development and pipeline responding to the needs of Patients.
The International science and research communities are challen-ging our healthcare with new innovative approaches to uses and studies with Medical Cannabis and hemp based CBD products.
The added challenge and issue for Patients who choose to experiment with Medical Cannabis in States and Countries where it has been legalized, is how to find safe products manufactured and rooted in science. Patients are desperate to find integrity with brands and services that represent best practices and standards ensuring ensuring safety, efficacy, and consistency.
Recently I had the incredible privilege to be introduced to a talented group of Scientists and Life Science innovators at GB Sciences. GBS is a diverse science based cannabis company with three business focuses. GBS has vertically fused Cannabis products, Life Sciences, and Cannabis genetics in house establishing turnkey solutions for the merging industries. I was impressed with the opportunity they posed for integrative healthcare ecosystem, this is what so many of us have envisioned to see evolve, the science leading the conversation between Patients and Providers.
A challenge facing both Patients and Providers today is determining if Cannabis is beneficial and whether to consider this option as an alternative treatment. Many Patients are reporting after exhausting traditional treatments, they feel they having nothing to lose to explore medical cannabis.
By Amy Berliner
GB Sciences Completes Nanotechnology Transfer